PSA Versus Imaging Monitoring in mCRPC - Alan Bryce

Monitoring prostate-specific antigen (PSA) vs. imaging monitoring in metastatic castration-resistant prostate cancer (mCRPC)

Biographies: 
E. David Crawford

Alan Bryce, MD

Related Content:
Prognostic significance of time to prostate-specific antigen (PSA)